Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters
Open Access
- 9 May 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 25694
Abstract
ATP-Binding Cassette transporters are involved in the efflux of xenobiotic compounds and are responsible for decreasing drug accumulation in multidrug resistant (MDR) cells. Discovered by structure-based virtual screening algorithms, bafetinib, a Bcr-Abl/Lyn tyrosine kinase inhibitor, was found to have inhibitory effects on both ABCB1- and ABCG2-mediated MDR in this in-vitro investigation. Bafetinib significantly sensitized ABCB1 and ABCG2 overexpressing MDR cells to their anticancer substrates and increased the intracellular accumulation of anticancer drugs, particularly doxorubicin and [3H]-paclitaxel in ABCB1 overexpressing cells; mitoxantrone and [3H]-mitoxantrone in ABCG2 overexpressing cells, respectively. Bafetinib stimulated ABCB1 ATPase activities while inhibited ABCG2 ATPase activities. There were no significant changes in the expression level or the subcellular distribution of ABCB1 and ABCG2 in the cells exposed to 3 μM of bafetinib. Overall, our study indicated that bafetinib reversed ABCB1- and ABCG2-mediated MDR by blocking the drug efflux function of these transporters. These findings might be useful in developing combination therapy for MDR cancer treatment.Keywords
This publication has 42 references indexed in Scilit:
- Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicinOncotarget, 2015
- Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agentsOncotarget, 2015
- Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2Oncotarget, 2014
- Ligand and Structure-Based Classification Models for Prediction of P-Glycoprotein InhibitorsJournal of Chemical Information and Modeling, 2013
- Multidrug Resistance Gene (MDR-1) and Risk of Brain Metastasis in Epithelial Ovarian, Fallopian Tube, and Peritoneal CancerAmerican Journal of Clinical Oncology, 2011
- Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.2010
- Breast cancer resistance protein (BCRP/ABCG2): New inhibitors and QSAR studies by a 3D linear solvation energy approachEuropean Journal of Pharmaceutical Sciences, 2009
- The Role of Efflux Pumps in Drug-Resistant Metastatic Breast Cancer: New Insights and Treatment StrategiesClinical Breast Cancer, 2007
- Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing bindingBiochemical Journal, 2004
- Characterization of Phosphorylation-defective Mutants of Human P-glycoprotein Expressed in Mammalian CellsJournal of Biological Chemistry, 1996